Longevity Investors Conference
What is Longevity?
Longevity is defined as "long life" or "a great duration of life."
The term comes from the Latin word longaevitās. In this word, you can see how the words longus (long) and aevum (age) combine into a concept that means an individual who lives a long time.
About Longevity Investors Conference
Longevity will be one of the largest, if not the largest, investment opportunity in the decades to come.
The Longevity Investors Conference provides relevant insights into the subject, expert education, investment opportunities, excellent networking opportunities and a great setting in an exclusive location.
The conference is targeting investors from (U)HNWIs, Family Offices, VCs, Private Equity Funds, Private Banks and Asset Managers.
Sub-topics are (radical) life-extension, rejuvenation and biostasis.
Ph.D., A.O. David A. Sinclair
Professor, Harvard University
David Sinclair is a tenured Professor of Genetics at Harvard Medical School. He is best known for his work on genes and small molecules that delay aging by boosting the body’s defenses and for being the first reprogram and rejuvenate tissuesin vivo.
He has published over 200 scientific papers, is a co-inventor on over 50 patent and patent applications, and has co-founded a dozen biotechnology companies in the areas of rare diseases, inflammation, vaccines, infectious disease detection, eye diseases, diabetes, fertility, cancer, and biosecurity.
His first book Lifespanbecame a New York Times best seller in 2019. He has a citation index (h-index) of 94, serves as founder and Co-Chief Editor of the scientific journal Aging, is a board member of companies, and has received 36 awards including being one of Australia's leading scientists under 45, the Australian Medical Research Medal, the NIH Director’s Pioneer award, TIME magazine’s list of the “100 most influential people in the world” and the “Top 50 people in healthcare.” In 2018, he became the equivalent of a knight as an Officer of the Order of Australia (AO) for his work in medical research, science communication, and national security.
Chief Science Officer, SENS Research Foundation
Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process.
He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging.
He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.
Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits (uncompensated) on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.
Co-Founder and Chairman of Juvenescence
Jim Mellon is a British entrepreneur and investor with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies.
Jim’s investment philosophy is underpinned by his ability to recognise emerging trends that give rise to new industries or major shifts in markets. This includes global financial crisis of 2008-2009, as foreseen in the first book Jim co-authored entitled Wake Up!, and subsequently in the new science and technologies detailed in Cracking the Code and Fast Forward.
More recently Jim has established himself as a leader in the nascent field of ageing research and longevity. His groundwork into the field is summarised in the book Juvenescence which he also co-authored.
Jim sits on the Board of Trustees of the Buck Institute for Research on Aging, and the American Federation for Aging Research (AFAR). He is also a trustee of Biogerontology Research Foundation and Lifeboat Foundation, is an Honorary Fellow of Oriel College at the University of Oxford and sits on the Advisory Board of the Milken Institute’s Centre for the Future of Aging. Jim has been honoured by the AFAR with the George E. and Marie J. Doty Award for his support of ageing research.
Director, Institute for Aging Research, Albert Einstein College of Medicine
Dr. Nir Barzilai serves as director of the Institute for Aging Research at the Albert Einstein College of Medicine. In addition, he is a founder and board member of CohBar Inc. Listed on the Russel 2000 Index, it develops therapeutics based on mitochondrial-derived peptides. He is a renowned expert and scientist in the study of the biology and genetics of aging.
He is also a founder and a Medical Consultant to Lifebiosciences, targeting therapeutics against the hallmark of aging. He is leading the TAME (Targeting Aging with MEtformin) multi-central study to show that aging can be a target in humans in support of changing the FDA indication that is relevant to targeting aging.
Dr. Barzilai is the recipient of many awards including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity Award. His work has been profiled by outlets such as the New York Times, BBC, PBS, and National Geographic. He received his MD from Technion-Israel Institute of Technology.
President & CEO, Buck Institute for Research on Aging
Dr. Eric Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Gladstone Institute at the University of California San Francisco (UCSF). Dr. Verdin is currently adjunct Professor of Medicine at UCSF and Adjunct Professor at the University of Southern California (USC).
Dr. Verdin studies how metabolism, diet, and small molecules impact epigenetic regulatory mechanisms, and thereby the aging process and its associated diseases. He is a highly cited scientist (top 1 percent) and has been recognized for his research with multiple awards including a fellowship from the American Association for the Advancement of Science, election to the American Society for Clinical Investigation, the Association of American Physicians, and Belgium’s Royal Academy of Medicine.
The Buck Institute, in the San Francisco Bay Area, is globally recognized as the pioneer and leader in the field of research on aging, the number one risk factor for chronic disease. For more information visit www.buckinstitute.org
Prof. João Pedro
Integrative Genomics of Ageing Group, University of Liverpool
Prof de Magalhaes graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and then obtained his PhD in 2004 from the University of Namur in Belgium. Following a postdoc with genomics pioneer Prof George Church at Harvard Medical School, in 2008 Prof de Magalhaes was recruited to the University of Liverpool. He now leads the Integrative Genomics of Ageing Group (http://pcwww.liv.ac.uk/~aging/). His lab studies the ageing process and how we can manipulate it to fend off age-related diseases and improve human health.
Prof de Magalhaes has authored over 100 publications and given over 100 invited talks, including three TEDx talks. He also makes regular media appearances (BBC, CNN, the Washington Post, the Financial Times and many others). Prof de Magalhaes is an advisor/consultant for various organizations, including nonprofit foundations, universities, investment funds and biotech companies.
Co-Founder, Apollo Health Ventures
Alexandra is a Co-Founder and Investment Director at Apollo Health Ventures, an early stage investment fund focused on developing interventions that enhance human health and longevity.
As a trained pharmacist and biomedical science PhD, Alexandra has always been following her passion for improving healthy longevity. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. After her PhD, Alexandra worked with The Boston Consulting Group where she specialized on Pharma and Biotech Strategy to drive the development of innovative therapeutics.
President and Managing Partner, Palo Alto Investors
Dr. Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge fund founded in 1989 with approximately $2 billion in assets invested in healthcare.
Board certified in radiology, Joon served on the clinical faculty at Stanford from 2000-2006. Joon has served on numerous boards, and he is currently a trustee of the Salk Institute. Joon and his wife Kimberly launched the $1 million Palo Alto Longevity Prize and donated $2 million to support the National Academy of Medicine's Longevity Grand Challenge. He received his M.D. from Duke Medical School and B.A. from Harvard College.
Prof. Andrew J.
Professor of Economics, London Business School
Andrew J. Scott is Professor of Economics, former Deputy Dean at London Business School and Research Fellow at the Centre for Economic Policy Research.
His research focuses on longevity, an ageing society, and fiscal policy and debt management and has been published widely in leading journals. His book with Lynda Gratton, The 100-Year Life, has been published in 15 languages, is an Amazon bestseller and was runner up in the FT/McKinsey Business Book of the Year Award 2016 and Japanese Business Book of the Year Award 2017. His recent 2020 book, The New Long Life, considers how the challenges and opportunities of social and technological ingenuity might shape a new age of longer lives.
He is currently on the advisory board of the UK’s Office for Budget Responsibility, the Cabinet Office Honours Committee (Science and Technology), co-founder of The Longevity Forum, a member of the UK government’s Longevity Council and the WEF council on Japan and a consulting scholar at Stanford University’s Center on Longevity.
His ground-breaking work on longevity, economics, and the value and effect technology and longevity combined, will have on the wider society, is shaped by his professional connections to academia, industry, social pioneers and policymakers around the world.
Andrew previously held positions at Oxford University, London School of Economics and Harvard University. His MA is from Oxford, his M.Sc. from the London School of Economics and his D.Phil from Oxford University.
Founder, R42 Institute
Ronjon Nag is founder of R42 Institute and is an Interdisciplinary Distinguished Careers Institute Fellow at Stanford University where he teaches courses for AI in healthcare. He has invented and deployed artificial intelligence systems for over three decades.
He received a PhD in engineering from Cambridge, an MS from MIT, the IET Mountbatten Medal at the Royal Institution, and was a Harkness Fellow at Stanford University. Companies he has co-founded or advised have been sold to Motorola, BlackBerry, and Apple.
Co-founder & Managing Director Deep Knowledge Group
Margaretta is Co-founder and Managing Director of Deep Knowledge Group, an international consortium of commercial and non-profit organizations active in DeepTech, Longevity, and Frontier Technologies. Margaretta has worked in the software industry in Silicon Valley for over 30 years. In the 1990s she was a core member of the team that developed the first Java based secure messaging software for stock trading platforms that is used today by some of the world's top multinational banks. She's been a core member of teams that have influenced important technical specifications and standards, including JDBC (Java Database Connectivity) and JMS (Java Messaging Service), that have helped advance the technology industry. She communicates frequently with top-tier media, researchers at top universities, and CEOs of AI companies.
Margaretta is Co-founder and Managing Partner of Deep Knowledge Ventures, Longevity Capital, and AI-Pharma Capital. She is co-founder of Longevity Bank, Longevity Card, Longevity FinTech Company, Deep Knowledge Analytics, and Aging Analytics Agency. She is President of U1 Technologies, an enterprise software company, and Co-founder of Jthereum an enterprise Blockchain company. Margaretta serves on the Board of Directors of the Bring Hope Humanitarian Foundation, and on the advisory boards of the AI Precision Health Institute at the University of Hawaii Cancer Center, the Longevity AI Consortium at King’s College London, Nanomedicine company NaNotics, First Longevity, and Robots Go Mental. She is co-author of Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History. She has published dozens of articles on AI and Longevity, and publishes weekly newsletters on DeepTech, FinTech, and the Longevity Industry with over 40,000 subscribers.
Partner at Kizoo
Patrick Burgermeister is an expert in life science investing with a double background in molecular biology (Biozentrum Basel) and business administration (HSG Sankt Gallen). He joined Kizoo in 2019 coming from the venture capital group BioMedPartners where he was one of the partners. Moreover, his industry career encompasses also banking (as a senior analyst for pharma/biotech) and pharma (as a senior portfolio manager at Novartis).
Patrick supports various biotech companies as a director on their boards, was a successful business developer for early-stage biotech companies and led collaboration and licensing deals with public and private companies. He headed business development at several companies including Apeiron Biologics and BioVersys.
President of the Board / Trustee, European Biostasis Foundation
Emil is the President of the Board and a trustee at European Biostasis Foundation based in Switzerland and the CEO at Tomorrow Biostasis GmbH based in Germany.
He has a strong background in medicine, cancer research and entrepreneurship. He has been CEO of multiple tech and medical companies, most recently as a Founder and CEO at Medlanes.
He’s a regular keynote speaker on future of healthcare topics, the overlap of healthcare, science and technology as well as an advisor on digitalization topics.
Emil holds a doctorate degree (summa cum laude)in medicine from the University Medical Center Göttingen and plans to dedicate the next decades of his life to Medical Biostasis and cryomedicine.
Phil Newman is Editor in Chief of www.Longevity.Technology, the key daily news platform for Longevity investment, research and new business.
As an international consultant for over 25 years Phil has delivered C-level management, marketing and business development expertise to start-ups, scale-ups and enterprises.
Market experience includes: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability. He is the founder of First Longevity which operates 2 digital businesses in the field of Longevity, including Crowd Longevity: the digital platform for equity funding Longevity start-ups and scale-ups.
CIO, The Singularity Group
Gregory Hung is The Singularity Group’s (TSG) Chief Investment Officer, a Swiss investment boutique and research house dedicated to making applied innovation investable across industries. It is also known for its global innovation Think Tank that feeds the unique investment strategy. TSG is the owner of the Singularity IndexTM and exclusive advisor to the Singularity Fund.
Previously, Gregory was Senior Portfolio Manager and Deputy Head Alternative Investments at Swisscanto Invest where he was responsible for Liquid Alternatives including hedge fund and cross-asset alternative risk premia (ARP) solutions. Before, he worked for UBS Global Asset Management as a Hedge Fund Analyst and Portfolio Manager.
Gregory holds a Master in Banking and Finance from University of St. Gallen (HSG) with an emphasis on quantitative finance, corporate finance and econometrics. He earned a Bachelor in Banking and Finance from University of Zurich and is a CAIA charterholder.
Sabinije von Gaffke is an internationally praised and awarded Moderator, Speaker, Entrepreneur and Impact Diplomat at the intersection of Tech, Leadership, Sustainability, Health, Science and Human Potential.
She has interviewed everyone from thought leaders, top politicians, CEOs, tech profiles, successful entrepreneurs to philanthropists and shared the stage with some of the world’s leading brands, companies, institutions and foundations.
Insatiably curious, a visionary, a catalyst and game-changer. Sabinije is also a passionate longevity seeker, mindfulness meditator, yoga teacher training certified and a wizard of a communicator and connector who skillfully facilitates and bridges dialogue between leaders, stakeholders, corporates, science, academia, governance and cross-industries.
As driven entrepreneur, she has gathered her experience and expertise and founded IMPACTFULNESS Ventures, an ecosystem partnering with innovative, sustainable and purpose-driven ventures addressing the SDGs.
Trained in 2019 at Singularity University ‘Executive Leadership Program’ in Silicon Valley in how to use exponential technologies to create scalable solutions to the global grand challenges of our time. Today she co-hosts the Singularity Chapter in Sweden.
Host, Longevity Investors Conference
Tobias Reichmuth is a serial entrepreneur and investor. Since 2019 he takes part in “Höhle der Löwen”, the Swiss version of the TV investor show “Shark-Tank”. He has invested in various tech start-ups, where he also holds advisory or board mandates.
In 2009 he has founded SUSI Partners, a EUR 1.5bn infrastructure fund manager with a focus on fighting climate change, after several years of strategy consulting experience at The Boston Consulting Group and after having sold his first company.
He has co-founded The Singularity Group, a Swiss/Luxembourg based fund-manager with a focus on exponential technology used in all sectors, as well as Crypto Finance Group, the leading institutional cryptocurrency service and infrastructure provider and asset manager. He is also the initiator and president of CFC St. Moritz, the world’s most exclusive blockchain and digital money investor conference.
Tobias has studied at the University of St. Gallen (lic. oec. HSG / MIM CEMS) and the European Business School in Oestrich-Winkel (Dr. rer. pol.) and has graduated from Singularity University’s executive program in 2016. Tobias plans to reach the age of 120 (at least) and is on a vegan diet since the end of 2019.
Host, Longevity Investors Conference
Marc is a serial entrepreneur who co-founded the party platform usgang.ch in his 20s (trade sale to Axel Springer Media). He is also a co-founder of amiando, a ticketing platform, which was purchased by Xing and was named “Global Technology Pioneer” by the World Economic Forum (WEF).
After these two exits Marc has been active as a fintech investor (Partner of NextGFI, Venture Partner of Orange Growth Capital, Advisory Board of FinLeap, ...) and he explored Bitcoin in 2012.
Today, Marc is a Board Member of Crypto Finance Group and CfC St. Moritz and part of the expert network for Blockchain and Digital Economy of the WEF.
Marc holds a master’s degree in law from the University of Zurich and did the Executive Program at Singularity University.
ONLINE - all times are Central Europe Time (CET)
12:00 Welcome address
Dr. Tobias Reichmuth / Marc P. Bernegger
12:10 What is longevity?
Dr. Aubrey de Grey
12:40 Where do we stand in research?
Ph.D., A.O. David A. Sinclair
The following is only for VIP delegates
13:20 How to invest in longevity? Fund approach (panel)
Dr. Alexandra Bause / Joon Yun moderated by Gregory Hung
13:50 How can you achieve longevity? (panel)
Dr. Nir Barzilai / Dr. Eric Verdin / Prof J Pedro Magalhaes moderated by Phil Newman
14:20 How to invest in longevity? Direct investment approach (panel)
Patrick Burgermeister /Jim Mellon / Dr. Ronjon Nag moderated by Margaretta Colangelo
14:50 Is society ready for longevity?
Prof. Andrew J. Scott
Dr. Emil Kendziorra
Marc P. Bernegger / Dr. Tobias Reichmuth
15:35 Virtual Networking
It was a pleasure to welcome all of the participants to Longevity Investors Conference! We hope that you enjoyed this experience.
For those who could not join or would like to learn more about this fascinating subject, which is longevity, we are preparing a video.
The video from the world's first Longevity Investors Conference can be purchased by clicking the button below. It will include the exclusive VIP part of the conference, covering topics of "How to invest in longevity?", "How can you achieve longevity?", "Is society ready for longevity?" and "Biostasis".
If you have questions, please feel free to contact us.
Longevity Investors Conference 2021 is planned to take place in the beautiful ski resort St. Moritz (Switzerland).
We are looking forward to welcoming you in St. Moritz.